Kenvue Inc (KVUE.N): 2nd Circuit Court of Appeals Decision on Lawsuits Against KVUE Alleging Connection Between Tylenol and Autism/ADHD

Research evidence excerpt

Kenvue Inc (KVUE.N): 2nd Circuit Court of Appeals Decision on Lawsuits Against KVUE Alleging Connection Between Tylenol and Autism/ADHD

Flash |

13 Jul 2026 13:12:18 ET │ 11 pages

Kenvue Inc (KVUE.N)

2nd Circuit Court of Appeals Decision on Lawsuits Against KVUE

Alleging Connection Between Tylenol and Autism/ADHD

CITI'S TAKE Neutral

Price (10 Jul 26 16:00) US$19.48 This morning the Second Circuit US Court of Appeals vacated and

Target price US$19.00 remanded for further proceedings the lawsuits against KVUE and other

companies, which allege a connection between Tylenol and autism. The Expected share price return -2.5%

Second Circuit US Court of Appeals ruled that a lower court judge had Expected dividend yield 4.3%

improperly excluded expert witness testimony presented by the plaintiffs Expected total return 1.8%

who allege that Tylenol use during pregnancy can cause autism and ADHD Market Cap US$37,402M

in children. Although there remains no firm scientific consensus that

currently supports a causal link between Tylenol and autism, we think the

Second Circuit US Court of Appeals’ decision to overturn the District

Court’s decision and return the case for further proceedings opens the Filippo Falorni, CFAAC

door to a potentially more favorable outcome for the plaintiffs. We believe +1-212-816-3743

this remains a key risk for KMB and KVUE stocks, with the acquisition filippo.falorni@citi.com

expected to close in 2H26.

Expert Witness Testimony Exclusion Details: This morning, the Second Circuit US

Court of Appeals vacated and remanded for further proceedings the lawsuits against

KVUE (and other companies), which allege a connection between Tylenol and

autism. The Second Circuit US Court of Appeals ruled that a lower court judge had